| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors |
|
Medicine details |
|
| Medicine name | asciminib (Scemblix®) |
| Formulation | 20 mg and 40 mg film-coated tablets |
| Reference number | 3849 |
| Indication | Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/06/2022 |
| NICE guidance | TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors |